Black patients who sought outpatient care for COVID-19 between January and July 2022 were 36% less likely than white patients to receive the antiviral pill Paxlovid, while Hispanic patients were 30% less likely than non-Hispanic patients to receive the treatment, according to a study released today by the Centers for Disease Control and Prevention, based on sites participating in the National Patient-Centered Clinical Research Network.

“Racial and ethnic disparities persist in outpatient COVID-19 treatment, even among older adults and patients with immunocompromise,” the authors said. “Expansion of programs focused on equitable outpatient COVID-19 treatment, including raising patient awareness using trusted sources, educating clinicians and other prescribers, and expanding patient access to prescribers, can facilitate equitable health outcomes.”

Related News Articles

Headline
The AHA is offering a new set of social messages and assets for February to encourage the public to get vaccinated and boosted against COVID-19. The new…
Headline
A Food and Drug Administration advisory committee unanimously voted today to recommend harmonizing the composition of all COVID-19 vaccine primary series and…
Headline
In a study released today by the Centers for Disease Control and Prevention, a single bivalent COVID-19 vaccine booster provided additional protection against…
Headline
A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series…
Headline
Evusheld may not prevent COVID-19 in immunocompromised individuals exposed to the XBB.1.5 omicron subvariant, because the treatment has failed to neutralize…
Headline
In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported…